Boehringer Ingelheim and US-based pharmacy store chain Walgreens have entered into a strategic partnership to optimise clinical trial recruitment and improve accessibility, inclusivity and equity.
This deal expects to use select Walgreens pharmacies as clinical trial sites for individuals with obesity, overweight, and type 2 diabetes, focusing on Phase III clinical research.
Go deeper with GlobalData
The initiative targets the dismantling of barriers to clinical trial participation, aiming to achieve equitable health representation, particularly among Black and Hispanic communities in the US.
These groups are claimed to have historically been facing underrepresentation in clinical trials and are more likely to be affected by obesity.
In addition to the partnership with Walgreens, Boehringer Ingelheim is collaborating with mobile community research site solutions provider EmVenio Research to introduce mobile community research units.
These units will extend the reach of trials, offering additional options for participation and aiming to set a new standard for inclusivity in patient outcomes.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe use of pharmacies and mobile units in clinical trials is said to be a robust approach to enhancing patient engagement.
Walgreens plans to leverage advanced, real-world insights to detect and enrol potential study participants, furthering the impact of the collaboration.
Boehringer Ingelheim US Medicine & Regulatory Affairs senior vice-president Lennart Jungersten said: “Boehringer is proud to embrace this community-centric approach to clinical research with Walgreens and EmVenio.
“By bringing clinical trials into the heart of local communities, we’re making them more accessible, helping to provide access to diverse populations with pressing health needs to participate in our clinical trials. Boehringer Ingelheim is committed to helping those living with overweight and obesity to transform lives for generations to come.”
In November 2023, Boehringer reported 14-week findings from the Phase II trial of BI 690517 plus standard-of-care including empagliflozin in chronic kidney disease patients.
